share_log

Retail Investors Who Hold 42% of Zhejiang Jingxin Pharmaceutical Co., Ltd. (SZSE:002020) Gained 5.7%, Insiders Profited as Well

Retail Investors Who Hold 42% of Zhejiang Jingxin Pharmaceutical Co., Ltd. (SZSE:002020) Gained 5.7%, Insiders Profited as Well

持有浙江京新药业股票的散户投资者(占公司股份的42%)获得了5.7%的收益,内部人员也获利了。
Simply Wall St ·  07/11 21:56

Key Insights

主要见解

  • Significant control over Zhejiang Jingxin Pharmaceutical by retail investors implies that the general public has more power to influence management and governance-related decisions
  • 50% of the business is held by the top 9 shareholders
  • Insider ownership in Zhejiang Jingxin Pharmaceutical is 25%
  • 零售投资者在掌控着京新药业方面具有重要的作用,这意味着普通公众拥有更多的权力来影响其管理和治理决策。
  • 前9大股东持有该业务的50%。
  • 京新药业的内部持股比例为25%。

If you want to know who really controls Zhejiang Jingxin Pharmaceutical Co., Ltd. (SZSE:002020), then you'll have to look at the makeup of its share registry. The group holding the most number of shares in the company, around 42% to be precise, is retail investors. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).

如果您想知道谁真正控制着京新药业股份有限公司 (SZSE:002020),那您就必须查看其股份名册的构成情况。该公司持有最多股份的集团为零售投资者,准确地说是约占公司股份总数的42%。也就是说,如果股票上涨,该集团将最受益(如果有下跌,则会损失最多)。

While retail investors were the group that benefitted the most from last week's CN¥499m market cap gain, insiders too had a 25% share in those profits.

虽然零售投资者是最受益的集团,从上周 CN¥49900 万的市值增长中获得了最多的股份,但内部人也拥有了 25% 的这些利润。

In the chart below, we zoom in on the different ownership groups of Zhejiang Jingxin Pharmaceutical.

在下面的图表中,我们放大了对京新药业不同所有权团体的观察。

big
SZSE:002020 Ownership Breakdown July 12th 2024
SZSE:002020 所有权分布 2024年7月12日

What Does The Institutional Ownership Tell Us About Zhejiang Jingxin Pharmaceutical?

机构投资者拥有京新药业的股份,并持有公司的一部分股份。这表明在专业投资者中具有一定信誉。但我们不能仅依靠这个事实,因为机构投资者有时会做出不好的投资,就像每个人一样。如果两个大型机构投资者同时试图卖出股票,股价大幅下跌是很常见的事情。因此,值得检查京新药业的过去收益轨迹(如下)。当然,还要记住还有其他因素需要考虑。

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

机构通常在向自己的投资者报告时会针对一个基准进行衡量,因此一旦某只股票被纳入主要指数,他们通常会更加热衷于该股票。我们预计大多数公司都会有一些机构在登记簿上,尤其是那些正在增长的公司。

We can see that Zhejiang Jingxin Pharmaceutical does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Zhejiang Jingxin Pharmaceutical, (below). Of course, keep in mind that there are other factors to consider, too.

SZSE:002020 收益和营业收入增长 2024年7月12日

big
SZSE:002020 Earnings and Revenue Growth July 12th 2024
京新药业不是由对冲基金持有。吕刚目前是该公司最大的股东,持有股份总数的21%。相比之下,第二和第三大股东持有该股票的约16%和4.6%。

Zhejiang Jingxin Pharmaceutical is not owned by hedge funds. Lv Gang is currently the company's largest shareholder with 21% of shares outstanding. In comparison, the second and third largest shareholders hold about 16% and 4.6% of the stock.

京新药业的最新数据显示,内部人占有相当比例的股份。其市值仅为92亿元人民币,而内部人拥有价值23亿元人民币的股票。这相当重要。大多数人会很高兴看到董事会与他们一起投资。您可能希望访问这个免费的图表,以显示内部人最近的交易。

We also observed that the top 9 shareholders account for more than half of the share register, with a few smaller shareholders to balance the interests of the larger ones to a certain extent.

我们还观察到,前9大股东持有超过股份注册的一半,还有一些小股东平衡大股东的利益。

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.

尽管研究公司机构所有权数据是有意义的,但了解分析师的情绪也很有意义,以了解市场的走向。因为有很多分析师正在跟踪这个股票,所以看看他们的预测可能是值得的。

Insider Ownership Of Zhejiang Jingxin Pharmaceutical

我们可以看到,非上市公司持有该公司已发行股票的16%。非上市公司可能是相关方。有时内部人通过持有非上市公司的股份,而不是以个人身份持有公开公司的股份来参与公司。虽然很难得出任何广泛的结论,但值得注意作为进一步研究的一个领域。

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

公司内部人员的定义可能是主观的,并在不同的司法管辖区之间有所不同。我们的数据反映了个人内部人员,至少包括董事会成员。管理层最终向董事会负责。然而,经理们成为执行董事会成员并不罕见,尤其是如果他们是创始人或首席执行官。

I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.

我通常认为内部人士持股是一件好事。但是,在某些情况下,它会使其他股东更难以对董事会的决定进行问责。

Our most recent data indicates that insiders own a reasonable proportion of Zhejiang Jingxin Pharmaceutical Co., Ltd.. It has a market capitalization of just CN¥9.2b, and insiders have CN¥2.3b worth of shares in their own names. That's quite significant. Most would be pleased to see the board is investing alongside them. You may wish to access this free chart showing recent trading by insiders.

股份科技公司不控制Zhejiang Jingxin Pharmaceutical。 Lv Gang目前拥有该公司21%的已发行股份。相比之下,第二和第三大股东持有约16%和4.6%的股份。

General Public Ownership

一般大众所有权

The general public-- including retail investors -- own 42% stake in the company, and hence can't easily be ignored. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

普通公众(包括散户投资者)拥有该公司的42%的股份,因此不能轻易被忽视。尽管这个群体不能完全掌控局面,但它确实可以对公司的经营方式产生实质上的影响。

Private Company Ownership

私有公司的所有权

We can see that Private Companies own 16%, of the shares on issue. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.

我们可以看到,非上市公司持有该公司已发行股票的16%。非上市公司可能是相关方。有时内部人通过持有非上市公司的股份,而不是以个人身份持有公开公司的股份来参与公司。虽然很难得出任何广泛的结论,但值得注意作为进一步研究的一个领域。

Next Steps:

下一步:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too.

我觉得查看公司的实际所有者非常有趣。但为了真正获得洞察力,我们需要考虑其他信息。

I like to dive deeper into how a company has performed in the past. You can find historic revenue and earnings in this detailed graph.

我喜欢更深入地了解公司过去的表现。您可以在以下详细图表中找到历史收益和收入。

But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.

但最终,决定该业务所有者将获得多大利益的是未来而非过去。因此,我们认为最好查看此免费报告,以了解分析师是否预测更光明的未来。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注:本文中的数据是使用最后一个财务报表日期结束的为期12个月的数据计算的。这可能与全年年度报告数据不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发